These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24654989)

  • 1. Proteomics of osteosarcoma.
    Bernardini G; Laschi M; Geminiani M; Santucci A
    Expert Rev Proteomics; 2014 Jun; 11(3):331-43. PubMed ID: 24654989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: a possible model for studying osteosarcoma origin and stemness.
    Di Fiore R; Fanale D; Drago-Ferrante R; Chiaradonna F; Giuliano M; De Blasio A; Amodeo V; Corsini LR; Bazan V; Tesoriere G; Vento R; Russo A
    J Cell Physiol; 2013 Jun; 228(6):1189-201. PubMed ID: 23129384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling human osteosarcoma in mice through 3AB-OS cancer stem cell xenografts.
    Di Fiore R; Guercio A; Puleio R; Di Marco P; Drago-Ferrante R; D'Anneo A; De Blasio A; Carlisi D; Di Bella S; Pentimalli F; Forte IM; Giordano A; Tesoriere G; Vento R
    J Cell Biochem; 2012 Nov; 113(11):3380-92. PubMed ID: 22688921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer stem cells in osteosarcoma.
    Brown HK; Tellez-Gabriel M; Heymann D
    Cancer Lett; 2017 Feb; 386():189-195. PubMed ID: 27894960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface proteomic analysis of differentiated versus stem-like osteosarcoma human cells.
    Gemei M; Corbo C; D'Alessio F; Di Noto R; Vento R; Del Vecchio L
    Proteomics; 2013 Nov; 13(22):3293-7. PubMed ID: 24106197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system.
    Arai K; Sakamoto R; Kubota D; Kondo T
    Proteomics; 2013 Aug; 13(15):2351-60. PubMed ID: 23712969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
    Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
    Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin.
    Zou J; Gan M; Mao N; Zhu X; Shi Q; Yang H
    Arch Med Res; 2010 Apr; 41(3):162-9. PubMed ID: 20682173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delineation of hypoxia-induced proteome shifts in osteosarcoma cells with different metastatic propensities.
    Song Z; Pearce MC; Jiang Y; Yang L; Goodall C; Miranda CL; Milovancev M; Bracha S; Kolluri SK; Maier CS
    Sci Rep; 2020 Jan; 10(1):727. PubMed ID: 31959767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma.
    Su Y; Wagner ER; Luo Q; Huang J; Chen L; He BC; Zuo GW; Shi Q; Zhang BQ; Zhu G; Bi Y; Luo J; Luo X; Kim SH; Shen J; Rastegar F; Huang E; Gao Y; Gao JL; Yang K; Wietholt C; Li M; Qin J; Haydon RC; He TC; Luu HH
    Oncogene; 2011 Sep; 30(37):3907-17. PubMed ID: 21460855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells.
    Rubio R; Abarrategi A; Garcia-Castro J; Martinez-Cruzado L; Suarez C; Tornin J; Santos L; Astudillo A; Colmenero I; Mulero F; Rosu-Myles M; Menendez P; Rodriguez R
    Stem Cells; 2014 May; 32(5):1136-48. PubMed ID: 24446210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mediator of RNA polymerase II transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis.
    Yu W; Zhang Z; Min D; Yang Q; Du X; Tang L; Lin F; Sun Y; Zhao H; Zheng S; He A; Li H; Yao Y; Shen Z
    Eur J Cancer; 2014 Apr; 50(6):1125-36. PubMed ID: 24565852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells.
    Tang QL; Zhao ZQ; Li JC; Liang Y; Yin JQ; Zou CY; Xie XB; Zeng YX; Shen JN; Kang T; Wang J
    Cancer Lett; 2011 Dec; 311(1):113-21. PubMed ID: 21835542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor β1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma.
    Zhang H; Wu H; Zheng J; Yu P; Xu L; Jiang P; Gao J; Wang H; Zhang Y
    Stem Cells; 2013 Mar; 31(3):433-46. PubMed ID: 23225703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
    Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
    Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic profiling of osteosarcoma cells identifies ALDOA and SULT1A3 as negative survival markers of human osteosarcoma.
    Chen X; Yang TT; Zhou Y; Wang W; Qiu XC; Gao J; Li CX; Long H; Ma BA; Ma Q; Zhang XZ; Yang LJ; Fan QY
    Mol Carcinog; 2014 Feb; 53(2):138-44. PubMed ID: 22949271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The promise of bone cancer proteomics.
    Byrum S; Montgomery CO; Nicholas RW; Suva LJ
    Ann N Y Acad Sci; 2010 Mar; 1192():222-9. PubMed ID: 20392240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma.
    Li Y; Dang TA; Shen J; Perlaky L; Hicks J; Murray J; Meyer W; Chintagumpala M; Lau CC; Man TK
    Proteomics; 2006 Jun; 6(11):3426-35. PubMed ID: 16673437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis.
    Haydon RC; Luu HH; He TC
    Clin Orthop Relat Res; 2007 Jan; 454():237-46. PubMed ID: 17075380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.
    Rainusso N; Brawley VS; Ghazi A; Hicks MJ; Gottschalk S; Rosen JM; Ahmed N
    Cancer Gene Ther; 2012 Mar; 19(3):212-7. PubMed ID: 22173710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.